If you're seeing this message, that means
JavaScript has been disabled on your browser
, please
enable JS
to make this app work.
No tags found
Companies
No companies found
Advanced Search
Newsfeed
Alerts
Saved Lists
Sign Up for Free
Login
Source: Pharamceutical Technology
Syntrix Biosystems: SX-682 by Syntrix Pharmaceuticals for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
SX-682 is under clinical development by Syntrix Pharmaceuticals and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Read full article »
Syntrix Biosystems's Competitors
|
Syntrix Biosystems's News
|
Syntrix Biosystems's Financials
Follow
Followers on Owler
2
Est. Annual Revenue
$25-100M
Est. Employees
100-250
CEO
Update CEO
CEO Approval Rating
- -/100
Read more
See Syntrix Biosystems company profile »
